Drilldown: Medicines

25B-NBOH (1) · 25B-NBOMe (1) · 25C-NBOH (1) · 25C-NBOMe (1) · 25I-NBOH (1) · 25I-NBOMe (1) · 25N-NBOMe (1) · 2C-B (1) · 2C-B-FLY (1) · 2C-C (1) · 2C-D (1) · 2C-E (1) · 2C-I (1) · 2C-P (1) · 2C-T-2 (1) · 2C-T-7 (1) · Allylescaline (1) · Bromo-DragonFLY (1) · Cholecalciferol (vitamin D3) (1) · DOB (1) · DOC (1) · DOI (1) · DOM (1) · Ergocalciferol (vitamin D2) (1) · Escaline (1) · Methallylescaline (1) · Proscaline (1) · TMA-2 (1) · Vitamin E (α-tocopherol; mixed natural and synthetic forms) (1)

None (25) · Drisdol, Calcidol; also many OTC preparations (1) · Generic; many OTC formulations (1) · Many OTC; Rx 50,000 IU also available (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (1) · 5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Very potent 5-HT2A agonist; long duration (1) · '"`UNIQ--vote-0000032A-QINU`"' D3 (cholecalciferol) is more potent at raising serum 25(OH)D per dose; D2 remains widely prescribed in the US Rx 50,000 IU formulation'"`UNIQ--ref-0000032B-QINU`"'. (1) · '"`UNIQ--vote-0000042C-QINU`"' D3 is more potent than D2 at raising and sustaining serum 25(OH)D per dose, and is the more common OTC formulation; D2 remains the dominant Rx 50,000 IU formulation in the US for historical reasons. (1)

None (26) · '"`UNIQ--vote-0000032C-QINU`"', '"`UNIQ--vote-0000032D-QINU`"', '"`UNIQ--vote-0000032E-QINU`"', '"`UNIQ--vote-0000032F-QINU`"' (1) · '"`UNIQ--vote-0000042D-QINU`"', '"`UNIQ--vote-0000042E-QINU`"', '"`UNIQ--vote-0000042F-QINU`"', '"`UNIQ--vote-00000430-QINU`"' (1) · '"`UNIQ--vote-000012CE-QINU`"', '"`UNIQ--vote-000012CF-QINU`"', '"`UNIQ--vote-000012D0-QINU`"' (1)

None (26) · Deficiency: 50,000 IU PO weekly for 8-12 weeks, then maintenance 800-2,000 IU/day; maintenance OTC dosing typically 800-2,000 IU/d (1) · Maintenance 800-2,000 IU PO daily; deficiency replacement 50,000 IU PO weekly for 8-12 weeks then maintenance, or equivalent daily dosing 5,000-10,000 IU/d (1) · Replacement: 15-30 mg (22.5-45 IU) daily; NASH: 800 IU daily; AREDS-2: 400 IU daily (in combination formula) (1)

None (26) · 100, 200, 400 IU softgels and capsules; many proprietary OTC blends; combined formulations (AREDS-2) (1) · 50,000 IU capsules (Rx); 8,000 IU/mL oral solution (Rx); 400-5,000 IU OTC tablets and softgels (1) · OTC 400, 1,000, 2,000, 5,000 IU softgels and tablets; Rx 50,000 IU capsules; liquid drops 400-2,000 IU/drop (1)

None (26) · No strict; Institute of Medicine UL 4,000 IU/d in adults for chronic use (1) · Not strictly fixed; long-term Upper Limit ~4,000 IU/d in adults (Institute of Medicine) (1) · UL 1000 mg (~1500 IU natural)/d in adults; routinely exceeded in older AREDS-1 trials (1)

None (25) · for severe malabsorption) (1) · IM (rare (1) · insufflated (1) · Oral (4) · PR (1)

None (25) · 45-75 min (oral) (1) · Days to weeks for tissue saturation (1) · Days to weeks to raise 25(OH)D; clinical effect on bone over months (1) · Weeks to raise 25(OH)D into reference range (1)

None (25) · 4-8 h (1) · Long; fat-soluble storage in adipose (1) · Long; fat-soluble, stored in adipose (1) · Weeks (fat-soluble) (1)

None (25) · Not well characterized (1) · ~24 hours (parent); ~15 days (25(OH)D); 25(OH)D stores persist for months'"`UNIQ--ref-00000330-QINU`"' (1) · ~24 hours (parent); ~15 days (25(OH)D); tissue stores months (1) · ~3-4 days plasma; adipose tissue stores last months (1)

None (25) · High with fat-containing meal; reduced in malabsorption (1) · Not well characterized (1) · ~75% (oral; absorption improved with fat-containing meal) (1) · ~75% (oral; fat-soluble, absorption requires intact biliary/lipid digestion)'"`UNIQ--ref-00000331-QINU`"' (1)

None (25) · Not established (1) · Safe at replacement doses; deficiency is itself a risk in pregnancy and lactation.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (2) · Safe at replacement doses; high-dose use generally avoided.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (25) · OTC (low-dose) and [[USLegal:Prescription only|Rx-only]] (50,000 IU and concentrated solutions) in US (1) · OTC (most) and [[USLegal:Prescription only|Rx-only]] (50,000 IU) in US (1) · OTC in US (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)